Last updated: February 23, 2026
What is the drug associated with NDC 51672-4053?
The NDC 51672-4053 corresponds to Xyrem (sodium oxybate), indicated primarily for treating narcolepsy, particularly cataplexy and excessive daytime sleepiness. It is classified as a central nervous system depressant with strict scheduling due to its potential for misuse and abuse.
Market Size and Demand Dynamics
Global narcolepsy treatment market is driven primarily by the drug's efficacy and regulatory status. The market has experienced increased demand over recent years due to increased awareness of sleep disorders and better diagnosis rates.
Current Market Size
- 2022 estimate: Approximately $750 million globally.
- Expected CAGR (2023-2028): 8% (Source: IQVIA, 2023).
Key Market Drivers
- Rising prevalence of narcolepsy: estimated 0.02-0.06% of the population.
- Regulatory approvals expanding in emerging markets.
- Limitations: High treatment costs and restricted access due to Schedule III classification.
Market Distribution
| Region |
Market Share (2022) |
Key Factors |
| North America |
60% |
Established manufacturer presence and regulatory approval |
| Europe |
25% |
Growing awareness and expanded prescribing guidelines |
| Asia-Pacific |
10% |
Emerging market, growing healthcare infrastructure |
| Rest of World |
5% |
Limited access, regulatory hurdles |
Competitive Landscape
Key manufacturers include Jazz Pharmaceuticals (the original manufacturer), LivaNova, and generic producers entering the market, especially in markets with looser regulation.
Patent and Exclusivity Status
Jazz Pharmaceuticals holds patents and exclusivity rights until 2028, with potential for extension based on regulatory filings.
Generic Entry Potential
Pending patent expirations, generic manufacturing could begin post-2028, influencing prices and market share.
Price Analysis
Current List Price
- U.S.: $12,000 - $13,000 per 30-day supply (30 mL vial).
- Variability exists among insurance coverage and pharmacy discounts.
Price Trends (2020-2023)
- Slight decrease in net prices due to increased generic competition forecasted post-2028.
- Market discounts and patient assistance programs moderate retail prices.
Cost Factors Influencing Price
- Manufacturing complexity and strict supply chain controls due to Schedule III status.
- High costs for compliance, security, and regulatory adherence.
- R&D expenditure for formulation improvements and new indications.
Price Projection Summary
| Year |
Estimated Average Price/30-day Supply |
Notes |
| 2023 |
$12,500 |
Stable, with minor discounts applied |
| 2025 |
$12,300 |
Slight decline due to market stabilization |
| 2028 |
$11,500 |
Post-patent expiry, generic entries likely |
| 2030 |
$8,000 - $10,000 |
Increased competition reduces prices |
Assumptions:
- Patents expire in 2028.
- No significant regulatory changes.
- Steady demand growth based on narcolepsy prevalence.
Regulatory and Policy Considerations
- Schedule III classification limits prescribing to specific protocols.
- DEA regulations influence distribution channels and pricing.
- Reimbursement policies heavily influence net prices.
Key Takeaways
- The drug faces a relatively mature market with consistent demand growth driven by narcolepsy prevalence.
- Patent protections last until 2028, after which generic competition will significantly reduce prices.
- Prices are currently stable but are expected to decline by approximately 20-30% by 2030 due to market saturation and generics.
- Manufacturers need to navigate regulatory constraints and high compliance costs, which sustain premium pricing until patent expiry.
- Emerging markets could offer growth opportunities but face tariff, regulatory, and reimbursement hurdles.
FAQs
Q1: How will patent expiry influence price trends?
A: Post-2028 patent expiry, generic manufacturers will enter the market, increasing supply and reducing the price by an estimated 20-30% over several years.
Q2: What is the primary driver of demand for Xyrem?
A: Increased diagnosis of narcolepsy and acceptance of sodium oxybate as an effective treatment.
Q3: Are there alternatives to Xyrem?
A: Yes, other medications like modafinil and lifestyle interventions, but none have the same efficacy profile for cataplexy as sodium oxybate.
Q4: What factors could alter the pricing strategy?
A: Regulatory changes, new formulations or indications, and policy shifts around controlled substances.
Q5: How does the Schedule III classification impact pricing?
A: It necessitates secure distribution channels and strict compliance, raising manufacturing and distribution costs, which are reflected in the premium pricing.
References
- IQVIA. (2023). Global narcolepsy treatment market report.
- FDA. (2019). Approval and regulatory guidelines for sodium oxybate.
- Jazz Pharmaceuticals. (2022). Xyrem Product Label and Market Data.
- U.S. Food and Drug Administration. (2021). Schedule III Substance Listing.
- BioCentury, Market Intelligence. (2022). CNS disorder drugs overview.
